See the DrugPatentWatch profile for Vigabatrin
Is vigabatrin API patent-covered in India?
I can’t determine the vigabatrin active pharmaceutical ingredient (API) patent status in India from the information provided here. A reliable “patent watch” requires checking India-specific patent documents (and linked proceedings) against the exact substance and use claims.
Which Indian patents would a vigabatrin “API watch” usually track?
In practice, watchlists for an API like vigabatrin focus on:
- Patents that claim the compound (vigabatrin) itself.
- Patents that claim a specific salt, polymorph, hydrate, or prodrug form (if claimed separately).
- Process patents for manufacturing the API (distinct from compound claims).
- Formulation or method-of-use patents (often still relevant if they block commercial launches even when the API is otherwise available).
- Patents on manufacturing intermediates or key steps, if they are claimed broadly.
To do an accurate watch, you need the precise target you care about (compound vs. process vs. dosage form vs. specific therapeutic use) and the product’s launch context in India.
How do I find the right vigabatrin patent records for India?
A solid approach is to search Indian patent databases using both the drug name and chemical identifiers:
- Search terms: “vigabatrin” and possible salts or spellings used in filings.
- Also search related terms you might see in filings (e.g., “gamma-vinyl GABA” if used as a synonym).
- Then check:
- Patent numbers and assignees/applicants
- Filing and grant dates
- Claim scope notes (compound vs. process vs. use)
- Status (pending/granted/expired)
- Any legal events affecting enforcement (revocation, opposition/appeal outcomes)
What does “patent watch” mean for India launch planning?
If you’re trying to time an India launch or estimate regulatory risk, you typically track:
- Expiry date(s): including any term adjustments or extensions that may apply to the specific grant.
- Whether related patents remain in force even after one patent expires (common with process, salt, or manufacturing claims).
- Whether legal challenges are ongoing in India (patent enforcement risk can change even if a patent is formally still listed as active).
Can generics sell vigabatrin in India if an API patent expires?
Even after API compound patent expiry, a generic company can still face barriers if any of these remain active in India:
- Process patents (for how the API is made).
- Method-of-use patents (for a specific indication or dosing regimen).
- Formulation patents for a finished dosage form.
So the watch has to cover more than just “API compound” unless you already know only compound claims exist for the relevant portfolio.
What I need from you to produce an India-specific patent watch
If you share any of the following, I can structure a more targeted watch framework and tell you exactly what to check next:
- Whether you mean vigabatrin API only, or also vigabatrin drug product in India
- Any known patent number(s), applicant/brand name(s), or company names you care about
- Your launch target timing (year) or the dossier type you’re preparing (if known)
- Whether you care about compound patents only or also process/formulation/use
Sources
None were provided with your request. If you want, paste the patent numbers/links you’ve found (or the relevant vigabatrin product/brand names), and I’ll help interpret what to watch in India and how to translate that into a launch-risk checklist.